Targeted nanoparticle-based drug delivery and diagnosis

Emerich, Dwaine F.; Thanos, Christopher G.

doi:10.1080/10611860701231810

Cited by 204 publications

(108 citation statements)

References 181 publications

(159 reference statements)

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…[37][38][39] In addition to particle size, the type and surface characteristics of nanoformulations contribute to the regulation of uptake. [40][41][42] Some nanoformulations are toxic due to the surfactants used in their preparation. Therefore, in this study we explored the feasibility of five different curcumin nanoformulations for cancer therapy based on cancer cell uptake, as well as their interaction with human plasma proteins and red blood cells.…”

Section: Resultsmentioning

confidence: 99%

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Yallapu¹,

Ebeling²,

Chauhan³

et al. 2011

IJN

View full text Add to dashboard Cite

Background Recent studies report curcumin nanoformulation(s) based on polylactic- co -glycolic acid (PLGA), β-cyclodextrin, cellulose, nanogel, and dendrimers to have anticancer potential. However, no comparative data are currently available for the interaction of curcumin nanoformulations with blood proteins and erythrocytes. The objective of this study was to examine the interaction of curcumin nanoformulations with cancer cells, serum proteins, and human red blood cells, and to assess their potential application for in vivo preclinical and clinical studies. Methods The cellular uptake of curcumin nanoformulations was assessed by measuring curcumin levels in cancer cells using ultraviolet-visible spectrophotometry. Protein interaction studies were conducted using particle size analysis, zeta potential, and Western blot techniques. Curcumin nanoformulations were incubated with human red blood cells to evaluate their acute toxicity and hemocompatibility. Results Cellular uptake of curcumin nanoformulations by cancer cells demonstrated preferential uptake versus free curcumin. Particle sizes and zeta potentials of curucumin nanoformulations were varied after human serum albumin adsorption. A remarkable capacity of the dendrimer curcumin nanoformulation to bind to plasma protein was observed, while the other formulations showed minimal binding capacity. Dendrimer curcumin nanoformulations also showed higher toxicity to red blood cells compared with the other curcumin nanoformulations. Conclusion PLGA and nanogel curcumin nanoformulations appear to be very compatible with erythrocytes and have low serum protein binding characteristics, which suggests that they may be suitable for application in the treatment of malignancy. These findings advance our understanding of the characteristics of curcumin nanoformulations, a necessary component in harnessing and implementing improved in vivo effects of curcumin.

show abstract

Section: Resultsmentioning

confidence: 99%

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Yallapu¹,

Ebeling²,

Chauhan³

et al. 2011

IJN

View full text Add to dashboard Cite

show abstract

“…Generally, the active targeting mechanism takes advantage of highly specific interactions between the targeting ligand and certain tissues or cells within the body to promote the accumulation of nanoparticles at a specific site or cell type for highly efficient immunization. 122,123 There is growing literature in this area, as described in the "Actively APC-targeting nanocarriers" section. These types of ligands mainly include antibodies, engineered antibody fragments, peptides and aptamers.…”

Section: Trafficking and Targeting Behavior Of Nano-adjuvants Under Dmentioning

confidence: 99%

Applications of nanomaterials as vaccine adjuvants

Zhu

Wang

Nie³

2014

Human Vaccines & Immunotherapeutics

133

View full text Add to dashboard Cite

Vaccine adjuvants are applied to amplify the recipient's specific immune responses against pathogen infection or malignancy. A new generation of adjuvants is being developed to meet the demands for more potent antigenspecific responses, specific types of immune responses, and a high margin of safety. Nanotechnology provides a multifunctional stage for the integration of desired adjuvant activities performed by the building blocks of tailor-designed nanoparticles. Using nanomaterials for antigen delivery can provide high bioavailability, sustained and controlled release profiles, and targeting and imaging properties resulting from manipulation of the nanomaterials' physicochemical properties. Moreover, the inherent immune-regulating activity of particular nanomaterials can further promote and shape the cellular and humoral immune responses toward desired types. The combination of both the delivery function and immunomodulatory effect of nanomaterials as adjuvants is thought to largely benefit the immune outcomes of vaccination. In this review, we will address the current achievements of nanotechnology in the development of novel adjuvants. The potential mechanisms by which nanomaterials impact the immune responses to a vaccine and how physicochemical properties, including size, surface charge and surface modification, impact their resulting immunological outcomes will be discussed. This review aims to provide concentrated information to promote new insights for the development of novel vaccine adjuvants.

show abstract

“…These properties can be used to overcome some of the limitations found in traditional vaccines [6]. Efforts with calcium adjuvants have continued, and work with calcium phosphate nanoparticles has had some preclinical success [7]. Calcium phosphate (CAP) and aluminium phosphate (alum) compounds have been approved as vaccine adjuvants for human use in several European countries [8].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Effects of Aluminum Phosphate and Calcium Phosphate Nanoparticles as Adjuvants in Vaccinated Mice

Issa¹,

Salim²,

Zidan³

et al. 2014

IJCEA

View full text Add to dashboard Cite

Abstract-The present study aim at studying the histological effects of both aluminum phosphate (Alum) and calcium phosphate (CAP) nanoparticles adjuvant in parallel with their potentials as adjuvant and the related immune response to tetanus toxoid vaccine adsorbed on both of them. Ninety Swiss albino mice were used in the experiment (50% adults and 50% juveniles). Mice were immunized intramuscularly with 0.125 ml adjuvanted tetanus toxoid vaccine. For alum adjuvant study, 27 adult mice and 27 juvenile ones were injected with alum adjuvanted vaccine and sacrificed weekly as triplects for 9 weeks. For calcium phosphate adjuvant study, 15 adult mice and 15 juvenile ones were injected with calcium phosphate adjuvanted vaccine and sacrificed weekly as triplects for 5 weeks. The effect of alum and calcium phosphate nanoparticles adjuvants in enhancing the immune response of tetanus toxoid vaccine were monitored through measurement of antibody titer in sera of mice. The pathological effect of both adjuvants were monitored through histological study of liver, brain, kidney and injected muscle of sacrificed animals. Recorded data revealed that both adjuvanted vaccine caused histopathological changes in tissues of liver, kidney, brain and injected muscle. On the other hand alum adjuvanted tetanus toxoid vaccine was more potent and showed higher antibody level than CAP adjuvanted vaccines.

show abstract

Targeted nanoparticle-based drug delivery and diagnosis

Cited by 204 publications

References 181 publications

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Applications of nanomaterials as vaccine adjuvants

Evaluation of the Effects of Aluminum Phosphate and Calcium Phosphate Nanoparticles as Adjuvants in Vaccinated Mice

Contact Info

Product

Resources

About